Recombinant protective antigen vaccines - Pfenex

Drug Profile

Recombinant protective antigen vaccines - Pfenex

Alternative Names: Glide anthrax vaccine; Px 563L; Px-563L SDI; Px563L-mrPA; RPA 563; rPA anthrax vaccine - Pfenex; SDI rPA anthrax vaccine - Pfenex

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfenex
  • Developer Immunovaccine; Pfenex; US Department of Health and Human Services
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Anthrax

Most Recent Events

  • 15 Mar 2018 Pfenex plans a phase II trial for Anthrax in USA in 2019
  • 01 Jun 2017 Pfenex completes a phase I trial in Anthrax (In volunteers, Prevention) in USA (IM) (NCT02655549)
  • 08 Aug 2016 Safety and immunogenicity results from a phase Ia trial in healthy volunteers released by Pfenex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top